CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:The potential of chimeric antigen receptor -T cell therapy for endocrine cancer.
The potential of chimeric antigen receptor -T cell therapy for endocrine cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
内分泌癌是一类相对罕见且异质性较高的肿瘤,临床表现多样;激素易于合成的特点进一步增加了内分泌癌治疗的复杂性。因此,开发安全有效的全身治疗方法(如嵌合抗原受体[CAR] T细胞疗法)对于改善患者预后至关重要。尽管该疗法治疗血液系统恶性肿瘤已取得良好结果,用于内分泌癌时仍面临多种并发症和挑战。本综述介绍CAR-T 细胞的制备,考察CAR-T 疗法治疗内分泌癌的潜力,列举与内分泌癌相关的重要抗原,总结该疗法面临的挑战,并阐述克服局限的策略。本文旨在提供有见地的观点,推动CAR-T 细胞疗法在内分泌癌领域的发展。
Endocrine cancer, a relatively rare and heterogeneous tumor with diverse clinical features. The facile synthesis of hormones further complicates endocrine cancer treatment.
Thus, the development of safe and effective systemic treatment approaches, such as chimeric antigen receptor (CAR) T cell therapy, is imperative to enhance the prognosis of patients with endocrine cancer. Although this therapy has achieved good results in the treatment of hematological malignancies, it encounters diverse complications and challenges in the context of endocrine cancer.
This review delineates the generation of CAR-T cells, examines the potential of CAR-T cell therapy for endocrine cancer, enumerates pivotal antigens linked to endocrine cancer, encapsulates the challenges confronted with CAR-T cell therapy for endocrine cancer, and expounds upon strategies to overcome these limitations. The primary objective is to provide insightful perspectives that can contribute to the advancement of CAR-T cell therapy in the field of endocrine cancer.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。